ALK-Rearranged Non–Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism
Alona Zer(Rambam Health Care Campus), Frances A. Shepherd(University Health Network), Natasha B. Leighl(Princess Margaret Cancer Centre), Elizabeth Dudnik(Rabin Medical Center), Ludmila Fridel(Rabin Medical Center), Nir Peled(Shaare Zedek Medical Center), Tzippy Shochat(Rabin Medical Center), Ming‐Sound Tsao(Kumamoto University), Ronald L. Burkes(Mount Sinai Hospital), Geoffrey Liu(Princess Margaret Cancer Centre), David Hwang(University Health Network), Mira Wollner(Technion – Israel Institute of Technology), Grzegorz Korpanty(University of Limerick), Anat Hershko Klement(Mount Sinai Hospital), Mor Moskovitz(Rambam Health Care Campus), Ronald Feld(University Health Network)
Cited by 100
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k